EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical Results for Cardiovascular Xenografts Treated With Novel Anticalcification Protocols

Hong-Gook Lim, Chang Ha Lee, Jae Hong Lim, Eung Re Kim, Yong Jin Kim iD

Artificial Organs · 2025

DOI: 10.1111/aor.15010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Organs, 2025. Verfasst von Hong-Gook Lim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Ko…. Hauptthemen laut MEDLINE: Pericardium, Bioprosthesis, Calcinosis, Tissue Scaffolds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: SNUH Lee Kun-hee Child Cancer & Rare Disease Project, Republic of Korea (Grant Number: 23C0220100).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glutaraldehyde (GA) generates cross‐links between cardiovascular xenografts to obtain tissue stability and attenuate antigenicity. However, the long‐term durability of GA‐fixed cardiovascular xenografts treated with previous anticalcification strategies has remained a challenge because tissue phospholipids, free aldehyde groups of GA, and residual antigenicity contribute to calcification. This study aimed to assess the safety, efficacy, and clinical performance of a bovine pericardial scaffold treated with our novel anticalcification protocols (Periborn) in patients with cardiovascular diseases.

Methods

Bovine pericardia were decellularized with 0.25% sodium dodecyl sulfate, 0.5% Triton X‐100, and treated with a space‐filler with polyethylene glycol. These tissues were cross‐linked with 0.5% GA in a 75% ethanol +5% octanol organic solvent and treated with glycine for detoxification to produce Periborn. Between July 2015 and April 2022, 451 Periborn patches were implanted in 352 cases for cardiovascular surgeries.

Results

The mean age at the time of surgery was 22.74 ± 20.09 years (13 days–89.5 years), follow‐up duration was 4.25 ± 2.56 years (17 days–8.6 years), and no patch‐related mortalities were observed. Five patients were reoperated owing to patch‐related complications including decreased mobility, erosion, pseudoaneurysm, and calcification, and the overall probability of freedom from Periborn‐related reoperation was 99.4% ± 0.4% at 1 year, 98.6% ± 0.7% at 5 years, and 95.4% ± 3.2% at 9 years.

Conclusions

This retrospective study demonstrates the safety and efficacy of the tissue‐engineered Periborn bovine pericardial scaffold for the surgical repair of various cardiovascular diseases. The excellent durability and hemodynamic performance of Periborn make our novel anti‐calcification protocol attractive and may require long‐term follow‐up to confirm durability and further research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PericardiumBioprosthesisCalcinosisTissue ScaffoldsCardiovascular DiseasesAnimalsHumansCattleFemaleMaleMiddle AgedAdultAgedGlutaralAdolescentYoung AdultChildHeterograftsAged, 80 and overChild, PreschoolRetrospective StudiesCross-Linking ReagentsTreatment Outcome

Stichwörter der Autor:innen

anticalcificationbioengineeringbiomaterialsdecellularizationxenograft

Substanzen

GlutaralCross-Linking Reagents

Autor:innen und Institutionen

  • Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
  • Department of Thoracic and Cardiovascular Surgery, Sejong General Hospital, Bucheon, South Korea.

ORCID-Profile: Yong Jin Kim

Förderung

  • SNUH Lee Kun-hee Child Cancer & Rare Disease Project, Republic of Korea (Grant Number: 23C0220100)

Zitieren

APA

Lim, H. G., Lee, C. H., Lim, J. H., Kim, E. R., & Kim, Y. J. (2025). Clinical Results for Cardiovascular Xenografts Treated With Novel Anticalcification Protocols. Artificial Organs. https://doi.org/10.1111/aor.15010

Vancouver

Lim HG, Lee CH, Lim JH, Kim ER, Kim YJ. Clinical Results for Cardiovascular Xenografts Treated With Novel Anticalcification Protocols. Artificial Organs. 2025. doi:10.1111/aor.15010

BibTeX
@article{Lim2025,
  author = {Lim, Hong-Gook and Lee, Chang Ha and Lim, Jae Hong and Kim, Eung Re and Kim, Yong Jin},
  title = {Clinical Results for Cardiovascular Xenografts Treated With Novel Anticalcification Protocols},
  journal = {Artificial Organs},
  year = {2025},
  doi = {10.1111/aor.15010}
}
Kostenlos starten →